CAR T-Cell Therapy | Clinical

Ide-Cel CAR T-Cell Therapy Demonstrates Promise in Heavily Pretreated Myeloma

January 16, 2021

Nina Shah, MD, discusses the potential role of idecabtagene vicleucel as treatment of patients with multiple myeloma.

Treating Double-Hit Lymphoma With CAR T-Cell Therapy and Other Drugs

January 04, 2021

During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.

Novel Bispecific Antibody Induces Encouraging Activity in B-Cell NHL

December 28, 2020

In an interview with Targeted Oncology, Rajat Bannerji, MD, PhD, discussed the early and encouraging findings from a novel bispecific antibody for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.

CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications

December 26, 2020

Multiple chimeric antigen receptor T-cell therapies for the treatment of lymphomas and multiple myeloma have moved forward in the regulatory process, with 1 new FDA approval in 2020 and others anticipated in the near future.

Addressing the Role of CAR T-Cell Therapy in Multiple Myeloma

December 22, 2020

Deepu Madduri, MD, discusses how chimeric antigen receptor T-cell therapy is used for patients with multiple myeloma.

Rolling BLA Submission Initiated for Cilta-Cel in R/R Multiple Myeloma

December 21, 2020

Rolling submission has been initiated for a Biologics License Application, submitting data to the FDA for the potential approval of ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma.

Novel CAR Approach Overcomes Resistance in CD58-Mutant Large B-Cell Lymphoma

December 05, 2020

Early data in mouse models have demonstrated that the novel approach of providing CD2 costimulation to CAR T cells in trans could reeestablish the efficacy of treatment in patients with CD58 mutations

First-In-Human Trial Shows Responses With Off-the-Shelf CAR T-Cell Therapy in Myeloma

December 05, 2020

The off-the-shelf CAR T-cell therapy ALLO-715, which targets BCMA, demonstrated responses as treatment of patients with heavily pretreated relapsed/refractory multiple myeloma in a first-in-human clinical trial.

Off-the-Shelf CAR T-Cell Products Show Potential in DLBCL

November 03, 2020

Loretta J. Nastoupil, MD, discusses the use of off-the-shelf chimeric antigen receptor T-cell products for the treatment of patients with diffuse large B-cell lymphoma and other cancers.

Novel Engineered CAR T Cells Show Early Promise in CD19+ B-Cell Malignancies

October 23, 2020

Chimeric antigen receptor T-cell therapy with the novel agent CTX110 showed promising early efficacy and safety as treatment of patients with relapsed or refractory CD19-positive B-cell malignancies who were treated in the phase 1 CARBON clinical trial.